Amplio Pharma

Amplio Pharma is a clinical-stage biotechnology company headquartered in the United Kingdom, dedicated to repurposing and reformulating existing drugs for the treatment of autoimmune and inflammatory diseases. The company's lead asset, AMP-101, is a proprietary formulation being developed for Systemic Lupus Erythematosus (SLE) to provide a more effective and safer alternative to current standard-of-care treatments. By leveraging the known safety profiles of established compounds, Amplio employs a de-risked development strategy to accelerate clinical timelines. The company is led by an experienced management team with a track record in drug discovery and translational medicine. Amplio's business model focuses on creating value-added medicines that address significant unmet needs in rheumatology and immunology.